• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估大肠杆菌Nissle1917衍生代谢产物对Toll样受体(TLR)信号通路关键调节基因的调控作用。

Evaluation of E. coli Nissle1917 derived metabolites in modulating key mediator genes of the TLR signaling pathway.

作者信息

Damoogh Sheyda, Vosough Mehrad, Hadifar Shima, Rasoli Masoumeh, Gorjipour Ali, Falsafi Sarvenaz, Behrouzi Ava

机构信息

Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran.

Department of Biology, Faculty of Science, Nourdanesh Institute of Higher Education, Isfahan, Iran.

出版信息

BMC Res Notes. 2021 Apr 26;14(1):156. doi: 10.1186/s13104-021-05568-x.

DOI:10.1186/s13104-021-05568-x
PMID:33902702
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8077910/
Abstract

OBJECTIVE

Gut-microbiota plays key roles in many aspects like the health and illness of humans. It's well proved that modification of gut microbiota by probiotics is useful for improving inflammatory bowel disease (IBD) conditions. According to recent studies, different types of bacterial metabolites can affect immune cells and inflammation conditions. The present study aimed to evaluate the anti-inflammatory effects of metabolites of E. coli Nissle1917.

RESULTS

The cell-free supernatant could modulate TNF-α production and affected many crucial mediators in the Toll-like receptor (TLR) signaling pathway. Also, supernatant showed significant dose-dependent properties in this regard. In this study, the TLR signaling pathway was found among probable mechanisms by which probiotics can affect inflammatory situations. These findings provide additional evidence on the use of probiotic metabolites for inhibiting and down-regulating numerous key mediator factors in the TLR signaling pathway. Aberrant or dysfunctional TLR signaling contributes to the development of acute and chronic intestinal inflammatory pathways in IBD. Therefore, finding a component that can affect this process might be considered for therapeutic targets in IBD patients.

摘要

目的

肠道微生物群在人类健康与疾病等诸多方面发挥着关键作用。益生菌对肠道微生物群的调节作用已被充分证明有助于改善炎症性肠病(IBD)状况。根据近期研究,不同类型的细菌代谢产物可影响免疫细胞和炎症状况。本研究旨在评估大肠杆菌Nissle1917代谢产物的抗炎作用。

结果

无细胞上清液可调节肿瘤坏死因子-α(TNF-α)的产生,并影响Toll样受体(TLR)信号通路中的许多关键介质。此外,上清液在这方面表现出显著的剂量依赖性。在本研究中,TLR信号通路是益生菌影响炎症状况的可能机制之一。这些发现为使用益生菌代谢产物抑制和下调TLR信号通路中的众多关键介质因子提供了更多证据。异常或功能失调的TLR信号传导会导致IBD中急性和慢性肠道炎症途径的发展。因此,寻找一种能够影响这一过程的成分可能被视为IBD患者的治疗靶点。

相似文献

1
Evaluation of E. coli Nissle1917 derived metabolites in modulating key mediator genes of the TLR signaling pathway.评估大肠杆菌Nissle1917衍生代谢产物对Toll样受体(TLR)信号通路关键调节基因的调控作用。
BMC Res Notes. 2021 Apr 26;14(1):156. doi: 10.1186/s13104-021-05568-x.
2
Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.益生菌对肠道、肠道炎性疾病及肝脏中免疫和炎性基因表达的调节作用。
World J Gastroenterol. 2014 Nov 14;20(42):15632-49. doi: 10.3748/wjg.v20.i42.15632.
3
Role of intestinal microbiota and metabolites in inflammatory bowel disease.肠道微生物群及其代谢物在炎症性肠病中的作用。
Chin Med J (Engl). 2019 Jul 5;132(13):1610-1614. doi: 10.1097/CM9.0000000000000290.
4
Probiotics and Probiotic-Derived Functional Factors-Mechanistic Insights Into Applications for Intestinal Homeostasis.益生菌和益生菌衍生的功能因子——应用于肠道稳态的机制见解。
Front Immunol. 2020 Jul 3;11:1428. doi: 10.3389/fimmu.2020.01428. eCollection 2020.
5
Inflammatory Bowel Diseases: The Role of Gut Microbiota.炎症性肠病:肠道微生物群的作用。
Curr Pharm Des. 2020;26(25):2951-2961. doi: 10.2174/1381612826666200420144128.
6
Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery.可编程益生菌通过有效的口服递送调节炎症和肠道微生物群,用于治疗炎症性肠病。
Nat Commun. 2022 Jun 14;13(1):3432. doi: 10.1038/s41467-022-31171-0.
7
Probiotics: The scientific evidence in the context of inflammatory bowel disease.益生菌:炎症性肠病背景下的科学证据。
Crit Rev Food Sci Nutr. 2017 Jun 13;57(9):1759-1768. doi: 10.1080/10408398.2014.941457.
8
Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.肠道微生物群介导的炎症性肠病治疗靶点的最新进展:未来药理学意义的新兴模式。
Pharmacol Res. 2019 Oct;148:104344. doi: 10.1016/j.phrs.2019.104344. Epub 2019 Aug 7.
9
Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases.辅助性T细胞17作为炎症性肠病潜在的益生菌治疗靶点
Int J Mol Sci. 2015 Sep 1;16(9):20841-58. doi: 10.3390/ijms160920841.
10
Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.目前对微生物群和饮食疗法治疗炎症性肠病的理解。
J Microbiol. 2018 Mar;56(3):189-198. doi: 10.1007/s12275-018-8049-8. Epub 2018 Feb 28.

引用本文的文献

1
Semen Microbiome, Male Infertility, and Reproductive Health.精液微生物群、男性不育与生殖健康
Int J Mol Sci. 2025 Feb 9;26(4):1446. doi: 10.3390/ijms26041446.
2
Gut instinct: harnessing the power of probiotics to tame pathogenic signaling pathways in ulcerative colitis.直觉:利用益生菌的力量来控制溃疡性结肠炎中的致病信号通路。
Front Med (Lausanne). 2024 Sep 11;11:1396789. doi: 10.3389/fmed.2024.1396789. eCollection 2024.
3
Porcine beta defensin 2 attenuates inflammatory responses in IPEC-J2 cells against Escherichia coli via TLRs-NF-κB/MAPK signaling pathway.

本文引用的文献

1
Colonization Dynamics of Multidrug-Resistant Are Dictated by Microbiota-Cluster Group Behavior over Individual Antibiotic Susceptibility: A Metataxonomic Analysis.多重耐药菌的定殖动态受微生物群落簇组行为而非个体抗生素敏感性的支配:一项宏分类学分析
Antibiotics (Basel). 2021 Mar 7;10(3):268. doi: 10.3390/antibiotics10030268.
2
Clinical Trials of Probiotic Strains in Selected Disease Entities.特定疾病实体中益生菌菌株的临床试验
Int J Microbiol. 2020 May 28;2020:8854119. doi: 10.1155/2020/8854119. eCollection 2020.
3
Probiotics for cancer alternative prevention and treatment.
猪β防御素 2 通过 TLRs-NF-κB/MAPK 信号通路抑制 IPPEC-J2 细胞对大肠杆菌的炎症反应。
BMC Vet Res. 2024 Aug 10;20(1):357. doi: 10.1186/s12917-024-04220-7.
4
PANoptosis: Novel insight into regulated cell death and its potential role in cardiovascular diseases (Review).PANoptosis:细胞程序性死亡调控的新视角及其在心血管疾病中的潜在作用(综述)。
Int J Mol Med. 2024 Sep;54(3). doi: 10.3892/ijmm.2024.5398. Epub 2024 Jul 4.
5
In vitro models and ex vivo systems used in inflammatory bowel disease.用于炎症性肠病的体外模型和离体系统。
In Vitro Model. 2022;1(3):213-227. doi: 10.1007/s44164-022-00017-w. Epub 2022 Apr 25.
6
The effect of probiotics on immunogenicity of spermatozoa in couples suffering from recurrent spontaneous abortion.益生菌对反复自然流产夫妇精子免疫原性的影响。
BMC Immunol. 2022 Jun 20;23(1):32. doi: 10.1186/s12865-022-00506-3.
7
Gut Microbiota and Bone Diseases: A Growing Partnership.肠道微生物群与骨疾病:日益紧密的联系
Front Microbiol. 2022 May 6;13:877776. doi: 10.3389/fmicb.2022.877776. eCollection 2022.
8
Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases.肝病进展中肠-肝轴的分子和细胞介质
Front Med (Lausanne). 2021 Sep 28;8:725390. doi: 10.3389/fmed.2021.725390. eCollection 2021.
益生菌在癌症防治中的应用。
Biomed Pharmacother. 2020 Sep;129:110409. doi: 10.1016/j.biopha.2020.110409. Epub 2020 Jun 18.
4
Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer.lncRNA、miRNA和mRNA相关ceRNA网络分析及耐药性非小细胞肺癌潜在药物靶点的鉴定
J Cancer. 2020 Mar 5;11(11):3357-3368. doi: 10.7150/jca.40729. eCollection 2020.
5
Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.毛花洋地黄苷 C 通过抑制 MAPK、Wnt、JAK-STAT 和 PI3K/AKT/mTOR 信号通路诱导 G2/M 细胞周期阻滞并抑制癌细胞生长。
Biomolecules. 2019 Nov 27;9(12):792. doi: 10.3390/biom9120792.
6
Chemical Composition and Antimicrobial Effectiveness of L. Essential Oil Against Multidrug-Resistant Isolates of and .薰衣草精油的化学成分和抗药性分离株的抗菌效果。
Molecules. 2019 Oct 26;24(21):3864. doi: 10.3390/molecules24213864.
7
A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease.炎症性肠病的诊断、预防及治疗方法综述
J Med Life. 2019 Apr-Jun;12(2):113-122. doi: 10.25122/jml-2018-0075.
8
Escherichia coli Nissle 1917 Protects Intestinal Barrier Function by Inhibiting NF-B-Mediated Activation of the MLCK-P-MLC Signaling Pathway.大肠杆菌 Nissle 1917 通过抑制 NF-B 介导的 MLCK-P-MLC 信号通路激活来保护肠道屏障功能。
Mediators Inflamm. 2019 Jul 3;2019:5796491. doi: 10.1155/2019/5796491. eCollection 2019.
9
Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids.治疗耐药菌的下一代策略:抗生素杂合体。
Indian J Med Res. 2019 Feb;149(2):97-106. doi: 10.4103/ijmr.IJMR_755_18.
10
Long-term in vitro 3D hydrogel co-culture model of inflammatory bowel disease.炎症性肠病的长期体外 3D 水凝胶共培养模型。
Sci Rep. 2019 Feb 12;9(1):1812. doi: 10.1038/s41598-019-38524-8.